title: Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
abstract: Budesonide is a topical steroid which after intestinal absorption is rapidly degraded into inactive metabolites in the liver. Its systemic bioavailability is only 10-15%. In the present open trial the efficiency and safety of oral pH-modified release budesonide were assessed in patients with active Crohn's ileocolitis. This report describes the results of the first 30 of 78 patients. After 6 weeks of treatment with 3 x 3 mg budesonide/day 67% of the patients were in clinical remission. Typical steroid-related side effects were observed in only one patient. Budesonide therefore seems to be suited as an alternative for classical steroids in patients with Crohn's ileocolitis. Its clinical efficacy is comparable with classical steroids but it's rate of steroid-related side effects is lower.
authors.affiliation: Department of Internal Medicine University of Regensburg, Mainz.
authors.forename: I
authors.initials: I
authors.lastname: Caesar
authors.forename: V
authors.initials: V
authors.lastname: Gross
authors.forename: M
authors.initials: M
authors.lastname: Roth
authors.forename: T
authors.initials: T
authors.lastname: Andus
authors.forename: C
authors.initials: C
authors.lastname: Schmidt
authors.forename: R
authors.initials: R
authors.lastname: Raedsch
authors.forename: A
authors.initials: A
authors.lastname: Weber
authors.forename: M
authors.initials: M
authors.lastname: Gierend
authors.forename: K
authors.initials: K
authors.lastname: Ewe
authors.forename: J
authors.initials: J
authors.lastname: Schölmerich
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019819:Budesonide; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D011282:Pregnenediones / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; D019819:Budesonide